Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov;20(11):799-813.
doi: 10.1038/s41571-023-00815-5. Epub 2023 Sep 25.

Drug-tolerant persister cells in cancer: the cutting edges and future directions

Affiliations
Free article
Review

Drug-tolerant persister cells in cancer: the cutting edges and future directions

Yi Pu et al. Nat Rev Clin Oncol. 2023 Nov.
Free article

Abstract

Drug-tolerant persister (DTP) cell populations were originally discovered in antibiotic-resistant bacterial biofilms. Similar populations with comparable features have since been identified among cancer cells and have been linked with treatment resistance that lacks an underlying genomic alteration. Research over the past decade has improved our understanding of the biological roles of DTP cells in cancer, although clinical knowledge of the role of these cells in treatment resistance remains limited. Nonetheless, targeting this population is anticipated to provide new treatment opportunities. In this Perspective, we aim to provide a clear definition of the DTP phenotype, discuss the underlying characteristics of these cells, their biomarkers and vulnerabilities, and encourage further research on DTP cells that might improve our understanding and enable the development of more effective anticancer therapies.

PubMed Disclaimer

References

    1. Saini, K. S. & Twelves, C. Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework. Br. J. Cancer 125, 155–163 (2021). - DOI - PubMed - PMC
    1. Soria, J. C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113–125 (2018). - DOI - PubMed
    1. Westover, D., Zugazagoitia, J., Cho, B. C., Lovly, C. M. & Paz-Ares, L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann. Oncol. 29 (Suppl. 1), i10–i19 (2018). - DOI - PubMed - PMC
    1. Long, G. V. et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med. 377, 1813–1823 (2017). - DOI - PubMed
    1. Dummer, R. et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III Melanoma. N. Engl. J. Med. 383, 1139–1148 (2020). - DOI - PubMed

Publication types